Acumen Pharmaceuticals Zukünftiges Wachstum
Future Kriterienprüfungen 0/6
Der Gewinn von Acumen Pharmaceuticals wird voraussichtlich um 6.6% pro Jahr zurückgehen, während der Jahresumsatz um 62.5% pro Jahr wachsen soll. Der Gewinn je Aktie wird voraussichtlich um 6.1% pro Jahr steigen. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -161.4% betragen.
Wichtige Informationen
-6.6%
Wachstumsrate der Gewinne
6.09%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 29.0% |
| Wachstumsrate der Einnahmen | 62.5% |
| Zukünftige Eigenkapitalrendite | -161.35% |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 14 Aug 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Alzheimer’s Trial And Cash Burn Will Test Risky Oligomer Bet Yet Long-Term Upside Remains
Catalysts About Acumen Pharmaceuticals Acumen Pharmaceuticals is a clinical stage biopharmaceutical company focused on antibody therapies that selectively target amyloid beta oligomers in Alzheimer’s disease. What are the underlying business or industry changes driving this perspective?
Oligomer Antibody And EBD Platform Will Reshape Early Alzheimer’s Treatment Over Time
Catalysts About Acumen Pharmaceuticals Acumen Pharmaceuticals is a clinical stage biotechnology company developing a beta oligomer targeted antibody therapies for Alzheimer's disease. What are the underlying business or industry changes driving this perspective?
Oligomer Antibody And Brain Delivery Advances Will Reshape Early Alzheimer Treatment Prospects
Catalysts About Acumen Pharmaceuticals Acumen Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing a beta oligomer targeted antibody therapies for Alzheimer’s disease. What are the underlying business or industry changes driving this perspective?Does Acumen Pharmaceuticals (NASDAQ:ABOS) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's
Summary Acumen Pharmaceuticals develops treatments for Alzheimer's disease targeting toxic AβOs, with promising results for sabirnetug in phase 1 clinical trial Intercept-AD. The potential for early AD is approximately 7 million patients, positioning ABOS for significant market share if successful. Sabirnetug’s Phase 1 trial showed promising results, reducing brain amyloid plaques and supporting its mechanism of action for treating early Alzheimer's disease. Acumen Pharmaceuticals has a healthy cash runway, estimated at 3.5 years, and appears undervalued relative to its peers in the biotech sector. Despite the promising data, investing in ABOS is speculative due to the early stages of research and the potential long timeline to FDA approval. Read the full article on Seeking AlphaIs Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Acumen Pharma at 11-month high on rivals’ Alzheimer’s data
The shares of microcap biotech Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) more than doubled in value on Wednesday after its rivals Biogen (BIIB) and Eisai (OTCPK:ESALF) (OTCPK:ESALY) announced promising late-stage data for experimental Alzheimer's therapy, lecanemab. In the trial involving nearly 1,800 patients, the amyloid targeting monoclonal antibody cut the cognitive and functional decline in the early stage of Alzheimer's by 27%, compared to placebo, the companies announced late Tuesday. With data validating the amyloid hypothesis in Alzheimer's, developers with similar drugs in their pipeline surged in value. Acumen (ABOS) is advancing its only drug candidate, ACU193 for Alzheimer's, with topline data from a Phase 1 trial expected in H1 2023. ACU193 is a humanized monoclonal antibody that selectively targets amyloid-beta oligomers, which, according to the company, are the most toxic and pathogenic form of amyloid-beta.Acumen Pharmaceuticals initiated at buy at H.C. Wainwright on Alzheimer's candidate
H.C. Wainwright has initiated Acumen Pharmaceuticals (NASDAQ:ABOS) with a buy rating saying the biopharma's early-stage Alzheimer's candidate, ACU193, has promise. The firm has a $15 price target (~207% return based on Wednesday's closing price). Unlike many other Alzheimer's therapies in development -- and marketed ones such as Biogen's (BIIB) Aduhelm (aducanumab) -- that target the removal of beta amyloid plaque from the brain, ACU193 works differently as a anti-amyloid-beta oligomer (AβO) monoclonal antibody. Analyst Andrew Fein noted that ACU193 "lacks the inflammatory effector functions of other [immunoglobulin] subclasses, thereby making it less prone to [amyloid-related imaging abnormalities], a major safety issue with current anti-[amyloid beta] therapies. Acumen (ABOS) said ACU193 prevents toxic AβOs from binding to dendritic spines and preserves neural function. The company added the candidate has the potential for disease slowing as well as cognitive improvement. The ongoing phase 1 trial is expected to enroll 62 subjects with mild cognitive impairment or mild dementia.We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 4 | -96 | -146 | -194 | 3 |
| 12/31/2027 | N/A | -134 | -141 | -153 | 5 |
| 12/31/2026 | N/A | -112 | -93 | -106 | 5 |
| 6/30/2026 | N/A | -105 | -92 | -92 | N/A |
| 3/31/2026 | N/A | -113 | -106 | -106 | N/A |
| 12/31/2025 | N/A | -121 | -116 | -116 | N/A |
| 9/30/2025 | N/A | -133 | -124 | -124 | N/A |
| 6/30/2025 | N/A | -137 | -118 | -118 | N/A |
| 3/31/2025 | N/A | -116 | -103 | -102 | N/A |
| 12/31/2024 | N/A | -102 | -86 | -86 | N/A |
| 9/30/2024 | N/A | -82 | -67 | -67 | N/A |
| 6/30/2024 | N/A | -65 | -56 | -56 | N/A |
| 3/31/2024 | N/A | -56 | -51 | -51 | N/A |
| 12/31/2023 | N/A | -52 | -43 | -43 | N/A |
| 9/30/2023 | N/A | -49 | -46 | -46 | N/A |
| 6/30/2023 | N/A | -46 | -42 | -42 | N/A |
| 3/31/2023 | N/A | -45 | -37 | -37 | N/A |
| 12/31/2022 | N/A | -43 | -35 | -35 | N/A |
| 9/30/2022 | N/A | -38 | -28 | -28 | N/A |
| 6/30/2022 | N/A | -32 | -26 | -26 | N/A |
| 3/31/2022 | N/A | -83 | -24 | -24 | N/A |
| 12/31/2021 | N/A | -101 | -18 | -18 | N/A |
| 9/30/2021 | 0 | -93 | -17 | -17 | N/A |
| 6/30/2021 | 1 | -92 | -11 | -11 | N/A |
| 3/31/2021 | 1 | -32 | -8 | -8 | N/A |
| 12/31/2020 | 1 | -7 | -7 | -7 | N/A |
| 12/31/2019 | 2 | -8 | N/A | -7 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: ABOS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Ertrag vs. Markt: ABOS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Hohe Wachstumserträge: ABOS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Einnahmen vs. Markt: ABOS wird im nächsten Jahr voraussichtlich keine Einnahmen haben.
Hohe Wachstumseinnahmen: ABOS wird im nächsten Jahr voraussichtlich keine Einnahmen haben.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: ABOS wird voraussichtlich in 3 Jahren unrentabel sein.
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/09/13 15:47 |
| Aktienkurs zum Tagesende | 2026/09/11 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Acumen Pharmaceuticals, Inc. wird von 7 Analysten beobachtet. 5 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Jason Zemansky | BofA Global Research |
| Thomas Shrader | BTIG |
| Pete Stavropoulos | Cantor Fitzgerald & Co. |